Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)
NCT04688164 is registered in ClinicalTrials.gov with Relmada Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)
- Lead sponsor
- Relmada Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 8, 2021
- Completion date
- November 10, 2022
- Enrollment
- 227 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.